发明授权
US08084442B2 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
有权
可用作单胺再摄取抑制剂的N，N-取代的3-氨基吡咯烷化合物
- 专利标题： N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
- 专利标题（中）： 可用作单胺再摄取抑制剂的N，N-取代的3-氨基吡咯烷化合物
-
申请号： US11914183申请日： 2006-05-12
-
公开(公告)号： US08084442B2公开(公告)日： 2011-12-27
- 发明人: Muneaki Kurimura , Shinichi Taira , Takahiro Tomoyasu , Nobuaki Ito , Kuninori Tai , Noriaki Takemura , Takayuki Matsuzaki , Yasuhiro Menjo , Shin Miyamura , Yohji Sakurai , Akihito Watanabe , Yasuyo Sakata , Takumi Masumoto , Kohei Akazawa , Haruhiko Sugino , Naoki Amada , Satoshi Ohashi , Tomoichi Shinohara , Hirofumi Sasaki , Chisako Morita , Junko Yamashita , Satoko Nakajima
- 申请人： Muneaki Kurimura , Shinichi Taira , Takahiro Tomoyasu , Nobuaki Ito , Kuninori Tai , Noriaki Takemura , Takayuki Matsuzaki , Yasuhiro Menjo , Shin Miyamura , Yohji Sakurai , Akihito Watanabe , Yasuyo Sakata , Takumi Masumoto , Kohei Akazawa , Haruhiko Sugino , Naoki Amada , Satoshi Ohashi , Tomoichi Shinohara , Hirofumi Sasaki , Chisako Morita , Junko Yamashita , Satoko Nakajima
- 申请人地址： JP Tokyo
- 专利权人： Otsuka Pharmaceutical Co., Ltd.
- 当前专利权人： Otsuka Pharmaceutical Co., Ltd.
- 当前专利权人地址： JP Tokyo
- 代理机构： Sughrue Mion, PLLC
- 优先权： JP2005-141230 20050513
- 国际申请： PCT/JP2006/309988 WO 20060512
- 国际公布： WO2006/121218 WO 20061116
- 主分类号： A61K31/40
- IPC分类号： A61K31/40 ; A61K31/497 ; A61K31/538 ; A61K31/695 ; A61K31/501 ; C07D207/12 ; C07D241/20 ; C07D403/12 ; C07D498/04 ; A61P25/00
摘要：
The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R101 and R102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.